BioCentury
ARTICLE | Clinical News

Glassia: Phase II/III started

March 10, 2014 7:00 AM UTC

Kamada began a double-blind, placebo-controlled, international Phase II/III trial to evaluate 60 and 120 mg/kg IV Glassia in 190 pediatric patients with newly diagnosed Type I diabetes. Interim data are expected after about 90 patients complete 1 year of treatment, which will be in about 2 years, according to the company. ...